Figure S10 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Year: 2026
Type: other
Abstract: Quantifiable CAR19 transgene levels in leukapheresis material and CAR22 products, and their correlation with CAR22 complete response (CR) rate and survival outcomes. (A) The CR rate is similar between patients with and without quantifiable CAR19 transgene levels in leukapheresis material and CAR22 products. (B) Progression-free survival (PFS) and overall survival (OS) are similar between patients with and without quantifiable CAR19 transgene levels in leukapheresis material. (C) PFS and OS are similar between patients with and without quantifiable CAR19 transgene levels in CAR22 products.
Authors: Yi-Jiun Su, Anne Marijn Kramer, Mark P. Hamilton, Neha Agarwal, Hrishikesh K. Srinagesh, John H. Baird, Bita Sahaf, Adam Kuo, Zachary J. Ehlinger, Moksha H. Desai, Skyler P. Rietberg, Ramya Tunuguntla, Shabnum Patel, Harshini Chinnasamy, Nikolaos Gkitsas-Long, Dorota D. Klysz, Annie Kathleen Brown, Sushma Bharadwaj, Saurabh Dahiya, Melody Smith, Lori Muffly, Crystal L. Mackall, Zinaida Good, Steven A. Feldman, David B. Miklos, Matthew J. Frank
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7165018070